From Drew Altman

Drew Altman is president and chief executive officer of KFF, a position he has held for more than 30 years since founding the modern-day KFF organization in the 1990s. He is a leading expert on national health policy issues and an innovator in health journalism and the nonprofit field.

View full bio | Read Dr. Altman's Beyond the Data columns

Photo of Drew Altman

President’s Message

“KFF is an independent source of health policy research, polling, and journalism. We have four major program areas: KFF Policy; KFF Polling; KFF Health News (formerly Kaiser Health News); and KFF Social Impact Media, which conducts specialized public health information campaigns. Learn more about the organization. 

What’s unique about KFF, however, can’t be found in any description of our programs because we’re more than a sum of our parts. KFF is a one-of-a-kind information organization. Not a policy research organization. Not a polling organization. And not a news organization. But rather, a unique combination of all three. That’s the vision behind KFF, and it's this combination that allows us to leverage our combined expertise and assets to play our national role on health policy.” Read more

Beyond the Data

In his “Beyond the Data” columns, Drew Altman discusses what the data, polls, and journalism produced by KFF mean for policy and for people.

Our Darwinian Approach to Health Care Costs

Our Darwinian Approach to Health Care Costs

In his latest column, President and CEO Dr. Drew Altman presents his Venn diagram of health care cost problems and shows how, in our fragmented health system, reducing one health cost problem often makes another worse.

Filter

221 - 230 of 333 Results

  • Health Care and the 2016 Debates

    From Drew Altman

    In this column for The Wall Street Journal’s Think Tank, Drew Altman discusses the lack of attention to health in the primary debates and last week's Democratic forum in South Carolina.

  • The Good and Bad of Those Ubiquitous Drug Ads

    From Drew Altman

    In this column for The Wall Street Journal's Think Tank, Drew Altman examines the public’s mixed views about prescription drug ads and their impact on prescribing patterns, based on a new survey.

  • Two Substantive Sides to Debate Over Obamacare’s ‘Cadillac Tax’

    From Drew Altman

    In this column for The Wall Street Journal’s Think Tank, Drew Altman says debate about whether to keep or repeal the Cadillac tax is more than a debate between sound policy and good politics, there are strong substantive arguments on both sides.

  • How Primary-Care Physicians Are Handling the Influx of Newly Insured

    From Drew Altman

    In this column for The Wall Street Journal's Think Tank, Kaiser’s President Drew Altman is joined by The Commonwealth Fund's President David Blumenthal to discuss the impact of the Affordable Care Act’s coverage expansion on the primary care delivery system.

  • Why Higher Drug Costs Are Consumers’ Biggest Cost Worry

    From Drew Altman

    In this column for The Wall Street Journal's Think Tank, Drew Altman discusses why public concern over drug prices is the “tip of the iceberg” representing broader concerns about out-of-pocket health care costs.

  • Will GOP Candidates’ Positions on Obamacare Matter in Crowded Field?

    From Drew Altman

    In this column for The Wall Street Journal's Think Tank, Drew Altman analyzes the politics of Republican Affordable Care Act replacement plans and the challenges all Republican candidates will face distinguishing themselves from others on the ACA in a crowded primary field.

  • What Post-Katrina New Orleans Shows About Urban and Race Issues

    From Drew Altman

    Drew Altman discusses a growing racial divide in the city about perceptions of economic opportunity for blacks and whites and what progress and challenges in New Orleans may mean for urban America in this column for The Wall Street Journal's Think Tank.